Abstract
The distribution and evolution of X4/R5 viral tropism during HIV-2 infection remains unknown. HIV-2 tropism was assessed in 83 antiretroviral-experienced patients with virological failure. Tropism was predicted as X4 in 58% of patients and was associated with a CD4 cell count of less than 100 cells/μl, and with a higher number of drug resistance mutations. This high prevalence of X4 virus might compromise the use of CCR5 inhibitors, currently mostly considered in HIV-2 salvage therapy of highly pretreated patients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
CCR5 Receptor Antagonists / therapeutic use*
-
CD4 Lymphocyte Count
-
Cyclohexanes / therapeutic use*
-
Disease Progression
-
Drug Resistance, Viral
-
Genotype
-
HIV Infections / drug therapy
-
HIV Infections / genetics
-
HIV Infections / immunology*
-
HIV-2* / physiology
-
Humans
-
Maraviroc
-
Prevalence
-
Receptors, CCR5 / drug effects*
-
Retrospective Studies
-
Triazoles / therapeutic use*
-
Viral Load
-
Viral Tropism*
Substances
-
CCR5 Receptor Antagonists
-
CCR5 protein, human
-
Cyclohexanes
-
Receptors, CCR5
-
Triazoles
-
Maraviroc